Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis

Research output: Contribution to journal › Review › Research › peer-review

Standard

Solid-state analysis for pharmaceuticals : Pathways to feasible and meaningful analysis. / Rantanen, Jukka; Rades, Thomas; Strachan, Clare.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 236, 115649, 2023.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Rantanen, J, Rades, T & Strachan, C 2023, 'Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis', Journal of Pharmaceutical and Biomedical Analysis, vol. 236, 115649. https://doi.org/10.1016/j.jpba.2023.115649

APA

Rantanen, J., Rades, T., & Strachan, C. (2023). Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis. Journal of Pharmaceutical and Biomedical Analysis, 236, [115649]. https://doi.org/10.1016/j.jpba.2023.115649

Vancouver

Rantanen J, Rades T, Strachan C. Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis. Journal of Pharmaceutical and Biomedical Analysis. 2023;236. 115649. https://doi.org/10.1016/j.jpba.2023.115649

Author

Rantanen, Jukka ; Rades, Thomas ; Strachan, Clare. / Solid-state analysis for pharmaceuticals : Pathways to feasible and meaningful analysis. In: Journal of Pharmaceutical and Biomedical Analysis. 2023 ; Vol. 236.

Bibtex

@article{8390c0587626476d9a048eae5da2aa57,
title = "Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis",
abstract = "The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.",
keywords = "Analytical techniques, Dosage form, Process analytics, Product performance, Sample preparation, Solid-state properties",
author = "Jukka Rantanen and Thomas Rades and Clare Strachan",
note = "Funding Information: This work has been supported by NordForsk (Oslo, Norway) - Nordic University Hub project Nordic POP (Patient Oriented Products; project number 85352 ). Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
doi = "10.1016/j.jpba.2023.115649",
language = "English",
volume = "236",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Solid-state analysis for pharmaceuticals

T2 - Pathways to feasible and meaningful analysis

AU - Rantanen, Jukka

AU - Rades, Thomas

AU - Strachan, Clare

N1 - Funding Information: This work has been supported by NordForsk (Oslo, Norway) - Nordic University Hub project Nordic POP (Patient Oriented Products; project number 85352 ). Publisher Copyright: © 2023 The Authors

PY - 2023

Y1 - 2023

N2 - The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.

AB - The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.

KW - Analytical techniques

KW - Dosage form

KW - Process analytics

KW - Product performance

KW - Sample preparation

KW - Solid-state properties

U2 - 10.1016/j.jpba.2023.115649

DO - 10.1016/j.jpba.2023.115649

M3 - Review

C2 - 37657177

AN - SCOPUS:85168993780

VL - 236

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

M1 - 115649

ER -

ID: 366305159